Kornimate/medical-research-clean huggingface dataset:
protocol based selective imaging versus routine computed tomography or ultrasound in suspected appendicitis

Conditions: Appendicitis

Summary: the goal of this clinical trial is to compare protocol based selective imaging to routine imaging in adult patients with suspected appendicitis. the main question\[s\] it aims to answer are: * does protocol based selective imaging using clinical scoring affect clinical outcome? * does protocol based selective observation combined with score based selective imaging affect clinical outcome? participants will be randomized into three groups: * selective imaging based on adult appendicitis score * selective observation based on appendicitis severity score combined with selective imaging based on adult appendicitis score * routine imaging using ultrasound and/or computed tomography researchers will compare selective imaging groups separately with routine imaging to see if number of negative appendectomies or number of complicated appendicitis is not significantly increased.


Eligibility criteria:
inclusion criteria: - suspicion of appendicitis exclusion criteria: * time from symptom onset over 72 hours * age \<18 years * pregnancy, ruled out by serum or urine hcg measurement in 18- to 49-year-old women * ct-scan or ultrasound already done within the last 3 days (72 hours) * clinical suspicion of other disease or other reason to perform imaging study * recruited earlier to the same trial
time to clearance of chlamydia trachomatis and neisseria gonorrhoeae rna after treatment: a prospective cohort study

Conditions: Chlamydia Trachomatis; Neisseria Gonorrhoeae; Uncomplicated Infections

Summary: the aim of this study is to evaluate the negativation time of chlamydial and gonococcal pcrs after treatment for urogenital, oropharyngeal and anal infections.


Eligibility criteria:
inclusion criteria: * - patients attending the trait d'union department at the nouvel hôpital civil for prep consultations, aes or hiv infection. * over 18 years of age * male or female * who have had an uncomplicated ct and/or ng infection treated with currently recommended therapies (ceftriaxone 500mg du for ng infections, doxycycline 200mg per day for 1 week for rectal ct infections and azithromycin 1g du or doxycycline 7 days for other ct infections). * subject affiliated to a social health insurance scheme * subject able to understand the aims and risks of the research and to give dated and signed informed consent exclusion criteria: * - complicated ct and/or ng infections: epididymitis, prostatitis, upper genital infection, extra-genital involvement (keratoconjunctivitis, arthritis, skin involvement, fiessinger-leroy-reiter syndrome, fitz-hugh-curtis syndrome). * interfering treatments and associated diseases: severe immunosuppression (hiv infection with cd4 less than 200/mm3, chemotherapy in the last 6 months, active haemopathy, congenital immune deficiency, immunosuppressive treatment including corticosteroid therapy for more than 4 weeks or organ transplant. * impossibility of giving the subject informed information (subject in an emergency situation, difficulties in understanding the subject, etc.). * subject under court protection * subject under guardianship or curatorship
pregnancy outcomes in women with unexplained recurrent pregnancy loss treated with low dose aspirin and unfractionated heparin

Conditions: Recurrent Pregnancy Loss

Summary: objective to determine maternal and fetal outcomes in women with unexplained rpl managed with aspirin or unfractionated heparin (ufh) plus aspirin during pregnancy. design: prospective clinical controlled study. setting: high-risk pregnancy unit- benha university hospital. methods: pregnant women with unexplained recurrent miscarriage attending high-risk pregnancy unit. 200 selected patients with previous unexplained recurrent miscarriage are divided into 2 groups: group a (n = 100) receive low-dose aspirin (81 mg once daily orally) plus heparin (5000 iu) every 12 h with the ﬁrst positive pregnancy test while group b (n = 100) receive no thing . main outcome measures: maternal outcomes included thromboembolic and haemorrhagic complications and pregnancy-induced hypertension .prematurity, intrauterine growth restriction and neonatal death were considered as maternal and fetal complications

this prospective comparative, controlled clinical study is conducted at department of obstetrics and gynecology, benha university hospital, and a private center, from june 2012 . after approval of the study protocol by the local ethical committee and obtaining written fully informed patients' consents. all patients are interviewed about their medical, personal, family, obstetrical and thrombosis history. all patients included in study complain of three or more unexplained consecutive spontaneous abortions. all patients (n=200) are in good general health without previous history of diabetes mellitus or thyroid dysfunction or cardiac disease. patients with thrombocytopenia (\<100000/ml), bleeding tendencies, ectopic pregnancy, past history of vascular thrombosis ,uterine anomalies and multiple gestation are excluded from the study. complete blood picture, urine routine examination, blood sugar, blood grouping, bleeding time, clotting time, prothrombin time, activated partial thromboplastin time, hepatitis b surface ag, hepatitis c virus screening are offered to all patients and findings noted as soon as they conceived. all patients are given routine folic acid, iron and calcium supplementation orally daily during antenatal period (whether conceived spontaneously or with treatment 200 selected patients with previous unexplained recurrent pregnancy loss are divided into 2 groups:group a (n = 100) are put on inj. ufh (cal-heparin) 5000 u subcutaneous twice daily plus aspirin 81 mg/day (juspirin) with the ﬁrst positive pregnancy test, inj. ufh is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously. while group b (n = 100) receive no thing

Eligibility criteria:
inclusion criteria: * patients with unexplained recurrent pregnancy loss (rpl) exclusion criteria: * previous history of diabetes mellitus or thyroid dysfunction or cardiac disease * thrombocytopenia (\<100000/ml) * bleeding tendencies * ectopic pregnancy * past history of vascular thrombosis * uterine anomalies * multiple gestation

Keywords: aspirin, heparin, pregnancy, recurrent pregnancy loss
bioequivalence study between two oral formulations of naproxen 500 mg tablets under fed conditions

Conditions: Bioequivalency

Summary: compare the rate and extent of absorption of two oral formulations of naproxen tablets, administered as a 1 x 500 mg tablet under fed conditions.


Eligibility criteria:
inclusion criteria: * healthy men or women, non-smoker, 18 years of age or older * willing to participate and sign a copy of the informed consent form exclusion criteria: * clinically significant illnesses or surgery within 4 weeks prior to study dosing * body mass index greater than or equal to 30.0 * recent history of drug or alcohol addiction or abuse * pregnant or lactating women * history of allergic response to naproxen, nsaids, or other related drugs, or to heparin * history of allergic reactions such as asthma, rhinitis, nasal polyps, urticaria, and hypotension associated with the use of aspirin or other nsaids * history or known presence of gastrointestinal ulceration, bleeding and perforation * use of tobacco products within 6 months prior to study dosing * evidence of a clinically significant disorder or whose laboratory results were deemed to be clinically significant * receipt of any drugs as part of a research study within 30 days prior to study dosing

Keywords: bioequivalency naproxen
single-arm phase ii study of ndure for patients with hnc

Conditions: Cancer of Head and Neck

Summary: this study will evaluate whether a new patient navigation intervention can decrease delays starting post-operative radiation therapy after surgery for white and african-american head and neck cancer patients.

this study will evaluate the feasibility, acceptability, preliminary clinical impact, and preliminary behavioral impact of ndure (navigation for disparities and untimely radiation therapy), our multi-level, theory-based navigation intervention to improve timely, equitable post-operative radiation treatment (port) among head and neck cancer (hnc) patients. we hypothesize that ndure will be feasible, acceptable, improve the timeliness of port for white and african american (aa) hnc patients and decrease disparities in delay between the two groups by improving system-, interpersonal-, and individual-level health behavior constructs.

Eligibility criteria:
in order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. age \> 18 years at the time of screening 2. histologically or pathologically confirmed invasive squamous cell carcinoma (scc) (or histologic variant) of the oral cavity, oropharynx (p16 positive, negative, or unknown), hypopharynx, larynx, unknown primary, paranasal sinuses, or nasal cavity. 3. american joint committee on cancer (ajcc) clinical stage grouping iii-iv (8th edition) for patients with scc of the oral cavity, p16-negative oropharynx, hypopharynx, larynx, paranasal sinuses, and nasal cavity; or ajcc clinical stage grouping iii-iv (7th edition) for patients with p16-positive scc of the oropharynx or unknown primary. 4. no prior exposure to radiation therapy, with or without concurrent chemotherapy, for treatment of hnscc in the definitive or adjuvant therapy settings 5. plan for curative intent surgery at musc 6. plan for port (at musc or non-musc) with or without concurrent chemotherapy following curative intent surgery an individual who meets any of the following criteria will be excluded from participation in this study: 1. self-identified hispanic ethnicity 2. presence of cognitive impairment that precludes participation as determined by oncology provider 3. prior radiation therapy for hnc 4. failure to undergo curative intent surgery at musc 5. lack of indication for port (with or without concurrent chemotherapy) per national comprehensive cancer network (nccn) guidelines based on final pathologic evaluation of adverse features and ajcc pathologic stage grouping

Keywords: cancer patient navigation
laryngeal mask in morbid obesity

Conditions: Morbid Obesity

Summary: investigators study the performance of both masks, proseal laryngeal mask airway (plma) and i-gel, as temporary ventilatory supraglottic airway devices (sgds) before tracheal intubation in morbidly obese patients. data are lacking in such population of patients

the available data regarding sgds in morbidly obese patients have focused mainly on plma. in general, sgds have been successfully used as temporary ventilatory devices before laryngoscope-guided tracheal intubation, conduits for endotracheal tube insertion, and primary airway devices during surgery. second-generation sgds are preferred for both rescue airway and routine use, compared with first-generation, non-gastric access devices. data on comparison plma vs. i-gel in morbidly obese patient are lacking. the plma is a second generation gastric access sgd. plma is composed of an airway tube that connects to a mask which, after insertion through the patient's mouth and inflation of cuff, forms an airtight seal on top the glottis allowing a secure airway to be managed by a health care provider. plma can be autoclaved and reused many times. i-gel is a new type of single use, second generation, gastric access sgd and doesn't have an inflatable cuff. because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature, thus minimising air leakage. the aim of this study is to compare plma and i-gel regarding insertion success rate, the time of insertion, gastric access tube positioning, oropharyngeal leak pressure, assessment of position by fiberoptic, ventilatory parameters and hemodynamic, and complications for each device placed before tracheal intubation in morbidly obese patients. this study is conducted at university medical hospital of padova, with approval from hospital research ethical committee and written informed consents from patients,. patients are randomly allocated into 2 equal groups, according to the inclusion and exclusion criteria. plma (n=35) in which plma is used for ventilation. i-gel (n=35) in which i-gel is used for ventilation. i

Eligibility criteria:
inclusion criteria: * morbidly obese patients scheduled for elective bariatric surgery under general anesthesia exclusion criteria: * nonfasting; symptoms or endoscopic evidence of gastroesophageal reflux, of gastric ulcer, or oropharyngeal pathology; known or predicted difficult airway; allergy to anesthetic and nonsteroidal antiinflammatory drugs; or inability to provide informed consent.
a study of rovalpituzumab tesirine to study cardiac ventricular repolarization in subjects with small cell lung cancer

Conditions: Small Cell Lung Carcinoma

Summary: study to evaluate the effect of rovalpituzumab tesirine on cardiac ventricular repolarization in subjects with small cell lung cancer (sclc).


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed extensive-stage small-cell lung cancer (sclc). * eastern cooperative oncology group (ecog) performance status of 0 to 2. * adequate hematologic and organ function as confirmed by laboratory values exclusion criteria: * clinically significant cardiac abnormalities including qrs duration of \>120 msec; qtcf \>470 msec for women and \>450 msec for men; abnormal cardiac rhythm; clinically significant cardiac valve abnormality; documented history of left ventricular ejection fraction \<0.30 within 6 months; permanent pacemaker or automatic implantable cardioverter defibrillator; history of torsades de pointes, congenital long qt syndrome, or family history of long qt syndrome or sudden death * recent or ongoing serious infection * women who are pregnant or breastfeeding * prior exposure to a pyrrolobenzodiazepine (pbd)-based drug, prior participation in a rovalpituzumab tesirine clinical trial, or known hypersensitivity to rovalpituzumab tesirine or excipient contained in the drug formulation.
an evaluation of a social network intervention for primary and secondary prevention of opioid overdoses

Conditions: Overdose

Summary: the purpose of this study is to pilot and implement a peer mentor intervention focused on overdose prevention and care. the intervention consists of 3 sessions. during the first and second session, each participant will meet individually with a trained staff member. in the 3rd session, the participant will invite a social network member to attend the session, and these 2 participants will meet with a trained staff member.

the specific aims of the study are: 1. conduct a pilot of an hiv/hcv/overdose prevention and care intervention for people who use opiates. 2. evaluate the feasibility of collecting donated drug preparation containers (i.e., cookers) to assess the presence of fentanyl, hcv, and hiv. 3. conduct a randomized controlled trial to assess efficacy of the experimental peer mentor condition on (a) overdose prevention and care education to drug network members, (b) naloxone availability, and (c) drug treatment readiness and entry. there are two types of participants: index participants and network participants. both type of participant will currently used opiates. participants will take part in a baseline visit and up to 3 follow-up visits. index participants will be randomized into the intervention or control arm of the study.

Eligibility criteria:
inclusion criteria for index participants: * self-reported use of opiates including heroin, fentanyl, or prescription opiates to get high at least 2 times in the last two weeks; * willing to invite a network member who uses drugs to the study; * ages 18-years or older; * living in the baltimore metropolitan region, and * not previously enrolled in the study or currently enrolled in another lighthouse study. inclusion criteria for network participants: * self-reported use of illicit injecting or non-injecting opiates at least 2 times in the last two weeks; * sees the index participant 2 or more times in the past week; * ages 18 years or older; and * living in the baltimore metropolitan region. exclusion criteria: * index participants may not take part in the study as a network participant. * network participants may not take part in the study as an index participant.

Keywords: peer education social networks
evaluation of oxygen delivery methods in acute exacerbations of chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease Exacerbation

Summary: to examine the effects of oxygen therapy methods applied as indicated in copd acute exacerbations on blood gas results and spirometric measurements.

patients requiring non-invasive ventilation will be divided into two groups: one group will receive nimv in the form of continuous positive airway pressure (cpap) or bi-level positive airway pressure (bipap). the other group will receive ezpap® (a non-invasive positive airway pressure device). for both groups, blood gas results and hand-held spirometer parameters, including forced vital capacity (fvc), peak expiratory flow (pef), and forced expiratory volume in one second (fev1), will be evaluated before and after the application.it is aimed to evaluate the effect of copd noninvasive treatment methods on hospitalization and mortality processes.

Eligibility criteria:
inclusion criteria: * patients with acute exacerbation of copd, * those without a history of trauma, * patients who have not undergone any lung surgery previously, * patients capable of providing written and verbal consent. exclusion criteria: * patients without acute exacerbation of copd, * pregnancy, suspected pregnancy, * those who have undergone any lung surgery previously, * patients with a history of trauma, * intubated patients and those not compliant with treatments, * patients unable to provide written and verbal consent.

Keywords: non-invasive ventilation ezpap® respiratory failure
effect of vitamin d on ventricular remodeling in patients with acute myocardial infarction (vitdami)

Conditions: Myocardial Infarction

Summary: to study the effect of calcifediol on left ventricular remodeling, mineral metabolism, plasma levels of several prognostic biomarkers and on endothelial function after an anterior myocardial infarction.


Eligibility criteria:
inclusion criteria: * age ≥ 40 years and maximum 85 years. * anterior myocardial infarction * sign informed consent exclusion criteria: * death during the index event * age younger than 40 or older than 85 years * previous infarction * more than 7 days in hospitalization * systemic inflammatory or autoimmune disease * concomitant disorders limiting survival * concomitant cardiomyopathy * left ventricular hypertrophy \> 16mm in females and \> 17mm in males * egfr\<45 * lvef\<30 * incomplete revascularization * valvular prosthesis * aortic stenosis with mean gradient\> 25 mmhg * moderate or severe valvular regurgitation * hypersensitivity or intolerance vitamin d supplement o excipient * blood calcium \>10.5 mg/dl * inability to follow. * difficulty in treatment compliance * contraindication for mri, including indication to place a cardiac device * indication of therapy with vitamin d. patient desires to take vitamin d. * drugs or conditions that interfere with the pharmacokinetics of calcifediol

Keywords: vitamin d myocardial infarction ventricular remodeling biomarkers
supporting the transition to and engagement in parenthood

Conditions: Trauma, Psychological; Prenatal Stress; Mental Health Issue; Maternal Distress

Summary: step (supporting the transition to and engagement in parenthood) is a manualized group intervention for pregnant women exposed to early life adversity designed to foster emotion regulation and reflective capacities in participants.


Eligibility criteria:
inclusion criteria: * pregnant women ages 18+ years * interested in reflecting about their experience of pregnancy and willing to attend weekly sessions in group setting. * must speak french as their first language exclusion criteria: * severe psychiatric disorders (schizophrenia, bipolar disorder) * severe emotional dysregulation * current self-harm * not sure to keep the child * high level of hostility

Keywords: mentalization maternal bonding trauma well-being attachment pregnancy
effect of prolonged slow expiration technique on blood gases among pneumatic neonates

Conditions: Pneumonia

Summary: pneumonia is a medical condition that, if not treated promptly, can lead to life- threatening complications. the prolonged slow expiration technique is a new type of chest physiotherapy that helps infants discharge bronchial secretions which accumulated due to pneumonia.

pneumonia is an infective lung condition that is one of the most common risk factors for neonatal death. pulmonary infections, most common caused by anaerobic bacterial infection, result in the accumulation of pus in the pleural cavity. preterms, neonates with respiratory infections, and underdeveloped lungs all require the use of a prolonged slow expiration technique. prolonged slow expiration technique is the only chest clearance technique that provides both effective clearance and a soothing effect. another recommendation for this technique is lack of application of emerging techniques of respiratory physiotherapy. although the technique is effective, it is rarely in practice over the conventional methods of chest physiotherapy. during prolonged slow expiration, intrathoracic pressure gradually rises due to thoracoabdominal compression, preventing bronchial collapse and flow disruption that occurs during forced expirations.

Eligibility criteria:
inclusion criteria: * age since birth till 2 months * clinical findings of pneumonia: tachypnea, chest recession, fever, cyanosis and cough * radiological diagnosis of pneumonia (x-ray): lober or segmental consolidation, nodular or coarse patchy infiltration, diffuse haziness and air bronchogram. * neonates on oxygen therapy. exclusion criteria: * neonates with congenital cardiopathy. * neonates with surgical incision in thorax or abdomen. * neonates with neurological intervention. * neonates with obstruction of upper air way. * neonates with gastroesophageal reflux and laryngeal affection.
aerosol inhalation treatment for dyspnea

Conditions: Healthy; Dyspnea

Summary: the purpose of this protocol is to develop and test optimal delivery of aerosol furosemide, a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.

this is study of aerosol treatment in a laboratory model of dyspnea in healthy subjects. this study is the first in a series of studies that will include investigation of a second dose in the laboratory and investigation of the treatment effect in hospitalized patients with refractory dyspnea. the outcome of this first study will determine the details of protocol for the succeeding studies.

Eligibility criteria:
inclusion criteria: * healthy exclusion criteria: * unstable heart or circulation disease * stroke * seizure disorder * severe migraine headaches * liver or kidney disease * adrenal gland problem (pheochromocytoma) * nerve problems that may affect your breathing sensation * brain cancer * drug or alcohol problem * systemic lupus erythematosis (sle) * high levels of depression, panic disorder, or other significant mental health problems * serious ongoing pain * pregnant * under 18 years old * not fluent in english

Keywords: dyspnea laboratory model of dyspnea in healthy subjects